Setipiprant(ACT-129968)

CAS : 866460-33-5

Ref. 3D-RJB46033

Informations sur le produit

• Nom: Setipiprant(ACT-129968)
• CAS: 866460-33-5

Description

Setipiprant is a CRTH2-selective antagonist, which has been shown to be effective in reducing the incidence of asthma exacerbations and bronchoconstriction. It also has a good safety profile with no significant adverse effects observed in clinical studies. Setipiprant binds to the CRTH2 receptor and blocks its activation by prostaglandin D2 (PGD2) or leukotriene B4 (LTB4). This inhibition prevents the release of inflammatory mediators from mast cells, which are responsible for airway inflammation in asthma. Setipiprant is being developed as a potential treatment for chronic asthma, allergic rhinitis, and chronic obstructive pulmonary disease (COPD). The molecule has been shown to bind to the CRTH2 receptor with an affinity that is about 10 times higher than that of cetirizine, another anti-inflammatory drug. This binding profile makes setipiprant an ideal candidate for treatment of inflammatory diseases

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 402.42 g/mol
• Formule: C₂₄H₁₉FN₂O₃
• Degré de pureté: Min. 95%